Platelet-activating factor receptor knockout mice are protected from MPTP-induced dopaminergic degeneration

Beom Keun Kim, Eun Joo Shin, Hyoung Chun Kim, Yoon Hee Chung, Duy Khanh Dang, Bae Dong Jung, Dae Hun Park, Myung Bok Wie, Won Ki Kim, Takao Shimizu, Toshitaka Nabeshima, Ji Hoon Jeong

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Platelet-activating factor (PAF), a potent mediator of inflammatory and immune responses, plays various roles in neuronal functions. However, little is known about the role of PAF/platelet-activating factor receptor (PAF-R) in Parkinson's disease. Treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) resulted in significant increases in PAF species in the striatum of wild-type mice. These increases paralleled PAF-R gene expression in wild-type mice. Although nuclear factor kappa B (NF-κB) DNA-binding activity was increased significantly in MPTP-treated wild-type mice, this increase was not significant in PAF-R antagonist ginkgolide B (GB)-treated mice or PAF-R knockout (PAF-R-/-) mice. Pyrrolidine dithiocarbamate (PDTC), an NF-κB inhibitor, significantly ameliorated the dopaminergic deficits induced by MPTP in wild-type mice. MPTP treatment significantly increased oxidative damage, the immunoreactivity of ionized calcium binding adaptor molecule 1 (Iba-1)-positive microglial cells, and microglial differentiation of the M1 type in the striatum of wild-type mice. Consistently, PDTC significantly attenuated MPTP-induced behavioral impairments in wild-type mice. However, dopaminergic deficits, oxidative damage, reactive microglial cells, and behavioral impairments induced by MPTP were not significantly observed in GB-treated mice or PAF-R -/- mice. PDTC did not significantly alter the attenuations evident in MPTP-treated PAF-R-/- mice, indicating that NF-κB is a critical target for neurotoxic modulation of PAF-R. We propose for the first time that PAF/PAF-R can mediate dopaminergic degeneration via an NF-κB-dependent signaling process.

Original languageEnglish
Pages (from-to)121-132
Number of pages12
JournalNeurochemistry International
Volume63
Issue number3
DOIs
Publication statusPublished - 01-01-2013

Fingerprint

Platelet Activating Factor
Knockout Mice
ginkgolide B
NF-kappa B
platelet activating factor receptor
4-phenyl-1,2,3,6-tetrahydropyridine
vpr Genes
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Parkinson Disease
Cell Differentiation

All Science Journal Classification (ASJC) codes

  • Cellular and Molecular Neuroscience
  • Cell Biology

Cite this

Kim, B. K., Shin, E. J., Kim, H. C., Chung, Y. H., Dang, D. K., Jung, B. D., ... Jeong, J. H. (2013). Platelet-activating factor receptor knockout mice are protected from MPTP-induced dopaminergic degeneration. Neurochemistry International, 63(3), 121-132. https://doi.org/10.1016/j.neuint.2013.05.010
Kim, Beom Keun ; Shin, Eun Joo ; Kim, Hyoung Chun ; Chung, Yoon Hee ; Dang, Duy Khanh ; Jung, Bae Dong ; Park, Dae Hun ; Wie, Myung Bok ; Kim, Won Ki ; Shimizu, Takao ; Nabeshima, Toshitaka ; Jeong, Ji Hoon. / Platelet-activating factor receptor knockout mice are protected from MPTP-induced dopaminergic degeneration. In: Neurochemistry International. 2013 ; Vol. 63, No. 3. pp. 121-132.
@article{66a879f3e9c0487a85b0e8e08ed19f1e,
title = "Platelet-activating factor receptor knockout mice are protected from MPTP-induced dopaminergic degeneration",
abstract = "Platelet-activating factor (PAF), a potent mediator of inflammatory and immune responses, plays various roles in neuronal functions. However, little is known about the role of PAF/platelet-activating factor receptor (PAF-R) in Parkinson's disease. Treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) resulted in significant increases in PAF species in the striatum of wild-type mice. These increases paralleled PAF-R gene expression in wild-type mice. Although nuclear factor kappa B (NF-κB) DNA-binding activity was increased significantly in MPTP-treated wild-type mice, this increase was not significant in PAF-R antagonist ginkgolide B (GB)-treated mice or PAF-R knockout (PAF-R-/-) mice. Pyrrolidine dithiocarbamate (PDTC), an NF-κB inhibitor, significantly ameliorated the dopaminergic deficits induced by MPTP in wild-type mice. MPTP treatment significantly increased oxidative damage, the immunoreactivity of ionized calcium binding adaptor molecule 1 (Iba-1)-positive microglial cells, and microglial differentiation of the M1 type in the striatum of wild-type mice. Consistently, PDTC significantly attenuated MPTP-induced behavioral impairments in wild-type mice. However, dopaminergic deficits, oxidative damage, reactive microglial cells, and behavioral impairments induced by MPTP were not significantly observed in GB-treated mice or PAF-R -/- mice. PDTC did not significantly alter the attenuations evident in MPTP-treated PAF-R-/- mice, indicating that NF-κB is a critical target for neurotoxic modulation of PAF-R. We propose for the first time that PAF/PAF-R can mediate dopaminergic degeneration via an NF-κB-dependent signaling process.",
author = "Kim, {Beom Keun} and Shin, {Eun Joo} and Kim, {Hyoung Chun} and Chung, {Yoon Hee} and Dang, {Duy Khanh} and Jung, {Bae Dong} and Park, {Dae Hun} and Wie, {Myung Bok} and Kim, {Won Ki} and Takao Shimizu and Toshitaka Nabeshima and Jeong, {Ji Hoon}",
year = "2013",
month = "1",
day = "1",
doi = "10.1016/j.neuint.2013.05.010",
language = "English",
volume = "63",
pages = "121--132",
journal = "Neurochemistry International",
issn = "0197-0186",
publisher = "Elsevier Limited",
number = "3",

}

Kim, BK, Shin, EJ, Kim, HC, Chung, YH, Dang, DK, Jung, BD, Park, DH, Wie, MB, Kim, WK, Shimizu, T, Nabeshima, T & Jeong, JH 2013, 'Platelet-activating factor receptor knockout mice are protected from MPTP-induced dopaminergic degeneration', Neurochemistry International, vol. 63, no. 3, pp. 121-132. https://doi.org/10.1016/j.neuint.2013.05.010

Platelet-activating factor receptor knockout mice are protected from MPTP-induced dopaminergic degeneration. / Kim, Beom Keun; Shin, Eun Joo; Kim, Hyoung Chun; Chung, Yoon Hee; Dang, Duy Khanh; Jung, Bae Dong; Park, Dae Hun; Wie, Myung Bok; Kim, Won Ki; Shimizu, Takao; Nabeshima, Toshitaka; Jeong, Ji Hoon.

In: Neurochemistry International, Vol. 63, No. 3, 01.01.2013, p. 121-132.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Platelet-activating factor receptor knockout mice are protected from MPTP-induced dopaminergic degeneration

AU - Kim, Beom Keun

AU - Shin, Eun Joo

AU - Kim, Hyoung Chun

AU - Chung, Yoon Hee

AU - Dang, Duy Khanh

AU - Jung, Bae Dong

AU - Park, Dae Hun

AU - Wie, Myung Bok

AU - Kim, Won Ki

AU - Shimizu, Takao

AU - Nabeshima, Toshitaka

AU - Jeong, Ji Hoon

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Platelet-activating factor (PAF), a potent mediator of inflammatory and immune responses, plays various roles in neuronal functions. However, little is known about the role of PAF/platelet-activating factor receptor (PAF-R) in Parkinson's disease. Treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) resulted in significant increases in PAF species in the striatum of wild-type mice. These increases paralleled PAF-R gene expression in wild-type mice. Although nuclear factor kappa B (NF-κB) DNA-binding activity was increased significantly in MPTP-treated wild-type mice, this increase was not significant in PAF-R antagonist ginkgolide B (GB)-treated mice or PAF-R knockout (PAF-R-/-) mice. Pyrrolidine dithiocarbamate (PDTC), an NF-κB inhibitor, significantly ameliorated the dopaminergic deficits induced by MPTP in wild-type mice. MPTP treatment significantly increased oxidative damage, the immunoreactivity of ionized calcium binding adaptor molecule 1 (Iba-1)-positive microglial cells, and microglial differentiation of the M1 type in the striatum of wild-type mice. Consistently, PDTC significantly attenuated MPTP-induced behavioral impairments in wild-type mice. However, dopaminergic deficits, oxidative damage, reactive microglial cells, and behavioral impairments induced by MPTP were not significantly observed in GB-treated mice or PAF-R -/- mice. PDTC did not significantly alter the attenuations evident in MPTP-treated PAF-R-/- mice, indicating that NF-κB is a critical target for neurotoxic modulation of PAF-R. We propose for the first time that PAF/PAF-R can mediate dopaminergic degeneration via an NF-κB-dependent signaling process.

AB - Platelet-activating factor (PAF), a potent mediator of inflammatory and immune responses, plays various roles in neuronal functions. However, little is known about the role of PAF/platelet-activating factor receptor (PAF-R) in Parkinson's disease. Treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) resulted in significant increases in PAF species in the striatum of wild-type mice. These increases paralleled PAF-R gene expression in wild-type mice. Although nuclear factor kappa B (NF-κB) DNA-binding activity was increased significantly in MPTP-treated wild-type mice, this increase was not significant in PAF-R antagonist ginkgolide B (GB)-treated mice or PAF-R knockout (PAF-R-/-) mice. Pyrrolidine dithiocarbamate (PDTC), an NF-κB inhibitor, significantly ameliorated the dopaminergic deficits induced by MPTP in wild-type mice. MPTP treatment significantly increased oxidative damage, the immunoreactivity of ionized calcium binding adaptor molecule 1 (Iba-1)-positive microglial cells, and microglial differentiation of the M1 type in the striatum of wild-type mice. Consistently, PDTC significantly attenuated MPTP-induced behavioral impairments in wild-type mice. However, dopaminergic deficits, oxidative damage, reactive microglial cells, and behavioral impairments induced by MPTP were not significantly observed in GB-treated mice or PAF-R -/- mice. PDTC did not significantly alter the attenuations evident in MPTP-treated PAF-R-/- mice, indicating that NF-κB is a critical target for neurotoxic modulation of PAF-R. We propose for the first time that PAF/PAF-R can mediate dopaminergic degeneration via an NF-κB-dependent signaling process.

UR - http://www.scopus.com/inward/record.url?scp=84879208877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879208877&partnerID=8YFLogxK

U2 - 10.1016/j.neuint.2013.05.010

DO - 10.1016/j.neuint.2013.05.010

M3 - Article

C2 - 23743065

AN - SCOPUS:84879208877

VL - 63

SP - 121

EP - 132

JO - Neurochemistry International

JF - Neurochemistry International

SN - 0197-0186

IS - 3

ER -